Clinical Trial Update: Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism [Phase 4]

View source ↗

Summary

A Phase 4 trial sponsored by Boehringer Ingelheim evaluated AT1-receptor antagonism in inflammation related to hypertension and coronary arteriosclerosis; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Arteriosclerosis
• Hypertension

Drugs mentioned

• Telmisartan (Telmisartan)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hypertension, Coronary Arteriosclerosis | Phase 4 | Status: COMPLETED